<a href="https://www.fiercebiotech.com/biotech/beone-agrees-2b-deal-option-preclinical-trispecific-antibody-chinas-huahui" hreflang="en">BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui </a>
BeOne Medicines has signed a $2 billion deal with China's Huahui Health for an exclusive option to license a preclinical trispecific antibody, HH160, which targets PD-1, CTLA-4, and VEGF-A for oncology applications. The agreement includes a $20 million upfront payment and potential milestone payments of up to $1.9 billion, along with tiered royalties on future sales.
The key takeaway for someone in your field is the strategic $2B deal between BeOne Medicines and Huahui Health for a preclinical trispecific antibody, highlighting the growing interest in multispecific antibody platforms for oncology. This agreement signifies potential high-value investment opportunities in innovative cancer therapies that leverage synergistic mechanisms to overcome monotherapy resistance. Additionally, BeOne's consideration of participating in Huahui’s future financing rounds may present further investment or collaboration opportunities.